[Product commercialization and BD authorization dual-line realization, a group of biopharmaceutical companies have increased their performance in the first three quarters] News on October 23, as of October 22, more than 40 companies in the A-share pharmaceutical and biological sector have disclosed their third quarter reports, and many companies have released performance forecasts for the first three quarters, of which more than 50% have achieved performance growth. The reporter found that the performance growth of listed pharmaceutical companies in the first three quarters has clear support: on the one hand, a number of products continue to increase in volume in the terminal market, and the results of commercialization are gradually emerging; on the other hand, down payments and milestone payments brought by external licensing transactions are gradually recognized as revenue. (Shanghai Securities News)